Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.78M | -19.09M | -17.75M | -17.53M | -15.96M |
| Total Depreciation and Amortization | 190.50K | 303.50K | 259.30K | 216.50K | 174.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 549.30K | -232.50K | 303.50K | 750.90K | 902.10K |
| Change in Net Operating Assets | 2.23M | 1.79M | 1.93M | 2.91M | 538.00K |
| Cash from Operations | -17.81M | -17.23M | -15.26M | -13.66M | -14.35M |
| Capital Expenditure | -12.60K | -14.60K | -16.40K | -12.10K | -18.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.38M | 192.90K | -254.00K | -513.40K | -911.40K |
| Cash from Investing | 3.37M | 178.20K | -270.40K | -525.50K | -930.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 66.70K | 66.70K | 54.70K | 54.70K | -- |
| Repurchase of Common Stock | -- | -500.00K | -500.00K | -500.00K | -500.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 66.70K | -433.30K | -445.30K | -445.30K | -500.00K |
| Foreign Exchange rate Adjustments | -49.50K | 12.90K | -15.50K | -33.20K | -28.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.43M | -17.47M | -15.99M | -14.66M | -15.81M |